Skip to main content
. Author manuscript; available in PMC: 2014 Jul 1.
Published in final edited form as: J Addict Med. 2013 Jul-Aug;7(4):277–286. doi: 10.1097/ADM.0b013e31829623f4

Figure 2. Weekly Differences Between Placebo and Varenicline on the Primary Outcome Measure, Percent Heavy Drinking Days, During Study Maintenance Phase (Weeks 2–13).

Figure 2

* p<.05; ** p<.01

Means are LSMEANS obtained during the maintenance period (Weeks 2-13) from a mixed model that includes treatment group, week, site, treatment goal, craving, baseline percent heavy drinking days, and treatment group by week interaction.

Error bars are standard errors.

Note: the treatment group by week interaction is statistically significant (p=0.011).